Beacon Genomics to Commercialize Genome-Wide CRISPR Off-Target Screens

Monica Heger, GenomeWeb, 12 May 2017,

CRISPR off-target effects is of significant concern during the transition of the system from a basic research tool to clinical settings.  The startup Beacon Genomics aims to aid in this process by offering NGS based, off-target screens: GUIDE-seq and CIRCLE-seq.  These non-biased methods rapidly screen the entire genome for potential off-target effects, enabling researchers and clinicians to optimize CRISPR/Cas treatment conditions.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply